Literature DB >> 21503779

Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.

Lucia Anna Muscarella1, Vito D'Alessandro, Annamaria la Torre, Massimiliano Copetti, Angelo De Cata, Paola Parrella, Marco Sperandeo, Fabio Pellegrini, Vincenzo Frusciante, Evaristo Maiello, Giuseppe Merla, Vito Michele Fazio, Gianluigi Vendemiale.   

Abstract

BACKGROUND: Somatostatin (SS) acts as a universal endocrine off-switch, and also inhibits the growth of neuroendocrine tumours through its specific receptors (SSTRs). Somatostatin receptors are G-protein-coupled receptors, which are encoded by five separate genes (SSTR1-5). Short peptide analogues demonstrate specific binding only for the subgroup consisting of SSTR2a, SSTR3 and SSTR5. Moreover, previous studies reported that expression of mRNA for SSTR2a correlated with therapeutic outcome in patients with carcinoid tumours treated with somatostatin analogs.
PURPOSE: To develop and apply a Real Time Quantitative PCR technique (RT-qPCR) to compare and contrast the mRNA levels of SSTR2a, SSTR3 and SSTR5 in Neuroendocrine Lung Cancer affected patients.
METHODS: Peripheral blood samples from 21 neuroendocrine lung cancer affected patients (14 SCLC, 6 LC and 1 LCNEC) subjected to scintigraphy with (111)In-DTPA-D-Phe(1)-octreotide (OctreoScan) and 24 healthy blood donors were investigated by RT-qPCR. mRNA levels for SSTR2a, SSTR3 and SSTR5 were measured in peripheral blood samples with a relative quantification method using plasmid dilutions as calibration curves and GAPDH as reference gene.
RESULTS: A statistically significant increase in target genes/GAPDH copy number ratio was found for SSTR2a (median 38; IQR 22-141) and SSTR5 (median 51; IQR 19-499) in neuroendocrine lung cancer affected patients as compared with samples from healthy blood donors (P ≤ 0.0003 and P ≤ 0.0005). Since low levels of expression were detected in the control group for all three genes, optimal cut-off values were assessed using ROC curve analyses and were equal to 9.05 for SSTR2a and 16.97 for SSTR5. These cut off values resulted in a sensitivity of 86% (95%IC 65-95) for both markers and a specificity of 83% (95%IC 64-93%) and 79% (95%IC 60-91%) for SSTR2a and SSTR5 respectively. Comparison between OctreoScan results and RT-qPCR analysis demonstrated agreement in 76% of the cases.
CONCLUSIONS: Our results suggest that SSTR2a and SSTR5 mRNAs are detectable in peripheral blood of neuroendocrine lung cancer affected patients using real-time quantitative PCR, with a good agreement with OctreoScan. The high sensitivity of this non-invasive molecular technique suggests that this method could represent a useful tool in the clinical management of neuroendocrine lung cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21503779     DOI: 10.1007/s13402-011-0025-9

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  19 in total

Review 1.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

2.  Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.

Authors:  Giselle F Taboada; Raul M Luque; Wildebranham Bastos; Renata F C Guimarães; Jorge B Marcondes; Leila M C Chimelli; Rosita Fontes; Paulo J P Mata; Paulo Niemeyer Filho; Denise P Carvalho; Rhonda D Kineman; Mônica R Gadelha
Journal:  Eur J Endocrinol       Date:  2007-01       Impact factor: 6.664

Review 3.  Oncological applications of somatostatin analogues.

Authors:  A V Schally
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

4.  Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors.

Authors:  N Kimura; M Pilichowska; F Date; I Kimura; M Schindler
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

Review 5.  Molecular pharmacology of somatostatin-receptor subtypes.

Authors:  C Bruns; G Weckbecker; F Raulf; K Kaupmann; P Schoeffter; D Hoyer; H Lübbert
Journal:  Ann N Y Acad Sci       Date:  1994-09-15       Impact factor: 5.691

Review 6.  The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors.

Authors:  K Oberg; B Eriksson; E T Janson
Journal:  Ann N Y Acad Sci       Date:  1994-09-15       Impact factor: 5.691

Review 7.  Neuroendocrine carcinomas of the gastrointestinal tract.

Authors:  V E Gould; W Jao; G Chejfec; B F Banner; P Bonomi
Journal:  Semin Diagn Pathol       Date:  1984-02       Impact factor: 3.464

8.  Tumor imaging and therapy using radiolabeled somatostatin analogues.

Authors:  Marion de Jong; Wout A P Breeman; Dik J Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Acc Chem Res       Date:  2009-07-21       Impact factor: 22.384

9.  Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.

Authors:  Miklos Pless; Christian Waldherr; Helmut Maecke; Carlos Buitrago; Richard Herrmann; Jan Mueller-Brand
Journal:  Lung Cancer       Date:  2004-09       Impact factor: 5.705

10.  Molecular detection of neuron-specific ELAV-like-positive cells in the peripheral blood of patients with small-cell lung cancer.

Authors:  Vito D'Alessandro; Lucia Anna Muscarella; Massimiliano Copetti; Leopoldo Zelante; Massimo Carella; Gianluigi Vendemiale
Journal:  Cell Oncol       Date:  2008       Impact factor: 6.730

View more
  10 in total

1.  Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics.

Authors:  J Clay Callison; Ronald C Walker; Pierre P Massion
Journal:  J Lung Cancer       Date:  2011

Review 2.  Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.

Authors:  Irvin M Modlin; Mark Kidd; Pier-Luigi Filosso; Matteo Roffinella; Anna Lewczuk; Jaroslaw Cwikla; Lisa Bodei; Agnieska Kolasinska-Cwikla; Kyung-Min Chung; Margot E Tesselaar; Ignat A Drozdov
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

3.  Epigenetic mechanisms of lung carcinogenesis involve differentially methylated CpG sites beyond those associated with smoking.

Authors:  Dusan Petrovic; Barbara Bodinier; Florence Guida; Marc Chadeau-Hyam; Sonia Dagnino; Matthew Whitaker; Maryam Karimi; Gianluca Campanella; Therese Haugdahl Nøst; Silvia Polidoro; Domenico Palli; Vittorio Krogh; Rosario Tumino; Carlotta Sacerdote; Salvatore Panico; Eiliv Lund; Pierre-Antoine Dugué; Graham G Giles; Gianluca Severi; Melissa Southey; Paolo Vineis; Silvia Stringhini; Murielle Bochud; Torkjel M Sandanger; Roel C H Vermeulen
Journal:  Eur J Epidemiol       Date:  2022-05-20       Impact factor: 12.434

4.  Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer.

Authors:  Javier Mariscal; Marta Alonso-Nocelo; Laura Muinelo-Romay; Jorge Barbazan; Maria Vieito; Alicia Abalo; Antonio Gomez-Tato; Casares de Cal Maria de Los Angeles; Tomas Garcia-Caballero; Carmela Rodriguez; Elena Brozos; Francisco Baron; Rafael Lopez-Lopez; Miguel Abal
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

5.  A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis.

Authors:  Mark Kidd; Irvin M Modlin; Ignat Drozdov; Harry Aslanian; Lisa Bodei; Somer Matar; Kyung-Min Chung
Journal:  Oncotarget       Date:  2017-12-29

6.  Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide.

Authors:  Ahmed A H Abdellatif; Heba A Abou-Taleb; Ahmed A Abd El Ghany; Ilka Lutz; Abdellatif Bouazzaoui
Journal:  Saudi Pharm J       Date:  2018-07-20       Impact factor: 4.330

Review 7.  Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review.

Authors:  Shista Priyadarshini; Derek B Allison; Aman Chauhan
Journal:  Pharmaceutics       Date:  2022-07-01       Impact factor: 6.525

8.  The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.

Authors:  Irvin M Modlin; Ignat Drozdov; Mark Kidd
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

9.  The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Authors:  Varune Rohan Ramnarine; Mohammed Alshalalfa; Fan Mo; Noushin Nabavi; Nicholas Erho; Mandeep Takhar; Robert Shukin; Sonal Brahmbhatt; Alexander Gawronski; Maxim Kobelev; Mannan Nouri; Dong Lin; Harrison Tsai; Tamara L Lotan; R Jefferey Karnes; Mark A Rubin; Amina Zoubeidi; Martin E Gleave; Cenk Sahinalp; Alexander W Wyatt; Stanislav V Volik; Himisha Beltran; Elai Davicioni; Yuzhuo Wang; Colin C Collins
Journal:  Gigascience       Date:  2018-06-01       Impact factor: 6.524

Review 10.  Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives.

Authors:  Lucia Anna Muscarella; Tommaso Mazza; Federico Pio Fabrizio; Angelo Sparaneo; Vito D'Alessandro; Antonio Tancredi; Domenico Trombetta; Flavia Centra; Silvana Pia Muscarella; Concetta Martina Di Micco; Antonio Rossi
Journal:  Cancers (Basel)       Date:  2021-03-16       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.